TI
MREO

tru Independence’s Mereo BioPharma MREO Stock Holding History

tru Independence’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-63
Closed – – 648
2020
Q2 		$0 Hold
63
– – ﹤0.01% 907
2020
Q1 		$0 Hold
63
– – ﹤0.01% 845
2019
Q4 		$0 Buy
+63
New +$161 ﹤0.01% 937

Other funds holding MREO

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

tru Independence's MREO Position: Q3 2020 in Review

tru Independence sold out of Mereo BioPharma (MREO) in Q3 2020, closing a stake of 63 shares.

tru Independence first reported a position in MREO in Q4 2019 and held it in 3 quarters. The position peaked at $0 in Q2 2020. 28 funds tracked by Wall St. Rank hold MREO as of Q3 2020.

  • tru Independence reported no remaining Mereo BioPharma position as of Q3 2020 after selling out during the quarter.
  • tru Independence sold 63 Mereo BioPharma shares in Q3 2020.
  • tru Independence first reported a position in Mereo BioPharma in Q4 2019 and held it in 3 quarters.
  • tru Independence's Mereo BioPharma position peaked at $0 in Q2 2020.
  • 28 funds tracked by Wall St. Rank held Mereo BioPharma as of Q3 2020.

Based on tru Independence's 13F filing for Q3 2020, filed 19 Nov 2020.